NCT03540485View on ClinicalTrials.gov

Safety and Efficacy of Melatonin in Patients with Multiple Progressive Primary Sclerosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Sclerosis, MultipleAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune Diseases
Interventions
DRUG

Melatonin

Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm

OTHER

Placebo

Daily administration of placebo orally, for 24 months between 10pm to 11pm

Trial Locations (3)

41009

RECRUITING

Virgen Macarena Hospital, Seville

41013

RECRUITING

Virgen del Rocio University Hospital, Seville

41950

RECRUITING

Hospital Vithas Nisa Sevilla, Seville

All Listed Sponsors
lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER